The present study replicates the previously observed dementia risk reduction with SGLT2 inhibitor versus DPP4 inhibitor initiation in people with diabetes [12–15], but limited studies with adequate events have explored the association between continuous use of SGLT2 inhibitors and dementia aetiologies [13]. The gene discussed is SLC5A2; the disease is diabetes mellitus.